CDK12: an emerging therapeutic target for cancer
Year: 2018
Type: review
Abstract: Cyclin-dependent kinase 12 (CDK12) belongs to the cyclin-dependent kinase (CDK) family of serine/threonine protein kinases that regulate transcriptional and post-transcriptional processes, thereby modulating multiple cellular functions. Early studies characterised CDK12 as a transcriptional CDK that complexes with cyclin K to mediate gene transcription by phosphorylating RNA polymerase II. CDK12 has been demonstrated to specifically upregulate the expression of genes involved in response to DNA damage, stress and heat shock. More recent studies have implicated CDK12 in regulating mRNA splicing, 3' end processing, pre-replication complex assembly and genomic stability during embryonic development. Genomic alterations in CDK12 have been detected in oesophageal, stomach, breast, endometrial, uterine, ovarian, bladder, colorectal and pancreatic cancers, ranging from 5% to 15% of sequenced cases. An increasing number of studies point to CDK12 inhibition as an effective strategy to inhibit tumour growth, and synthetic lethal interactions have been described with MYC, EWS/FLI and PARP/CHK1 inhibition. Herein, we discuss the present literature on CDK12 in cell function and human cancer, highlighting important roles for CDK12 as a clinical biomarker for treatment response and potential as an effective therapeutic target.
Source: Journal of Clinical Pathology
Institution: Fred Hutch Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: G288060127, An integrated computational and functional genomics discovery engine for preclini, An Academic-Industry Partnership to Advance Functional Genomics for Personalized Oncology., Personalized cancer models to discover and develop new therapeutic targets., G729857754, 2/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch, 1/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch
OpenAlex ID: W2887071858
